Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
Thalidomide is an effective agent for advanced refractory or relapsed multiple myeloma (MM), although dose-limiting toxicity (DLT) may limit its use. This Phase I study found that a combination of low-dose thalidomide with bendamustine and prednisolone (BPT) maintained or increased efficacy, whilst...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
24 September 2008
|
| In: |
British journal of haematology
Year: 2008, Volume: 143, Issue: 2, Pages: 191-200 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/j.1365-2141.2008.07076.x |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1365-2141.2008.07076.x Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2008.07076.x 
|
| Author Notes: | Wolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, Franz Albert Hoffmann, Thomas Boldt, Andreas Schwarzer, Ute Ritter, Robert Rohrberg, Elke Schwalbe, Jens Uhlig, Thomas Zehrfeld, Veronika Schirmer, Antje Haas, Ute Kreibich and Dietger Niederwieser for the East German Study Group of Haematology and Oncology (OSHO) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1786118777 | ||
| 003 | DE-627 | ||
| 005 | 20230428030400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220114s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-2141.2008.07076.x |2 doi | |
| 035 | |a (DE-627)1786118777 | ||
| 035 | |a (DE-599)KXP1786118777 | ||
| 035 | |a (OCoLC)1341437121 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pönisch, Wolfram |d 1954- |e VerfasserIn |0 (DE-588)1146708629 |0 (DE-627)1005910073 |0 (DE-576)189466863 |4 aut | |
| 245 | 1 | 0 | |a Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy |b results of a Phase I clinical trial |c Wolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, Franz Albert Hoffmann, Thomas Boldt, Andreas Schwarzer, Ute Ritter, Robert Rohrberg, Elke Schwalbe, Jens Uhlig, Thomas Zehrfeld, Veronika Schirmer, Antje Haas, Ute Kreibich and Dietger Niederwieser for the East German Study Group of Haematology and Oncology (OSHO) |
| 264 | 1 | |c 24 September 2008 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.01.2022 | ||
| 520 | |a Thalidomide is an effective agent for advanced refractory or relapsed multiple myeloma (MM), although dose-limiting toxicity (DLT) may limit its use. This Phase I study found that a combination of low-dose thalidomide with bendamustine and prednisolone (BPT) maintained or increased efficacy, whilst avoiding DLT in 28 patients with MM that was refractory or that had relapsed after conventional chemotherapy or high-dose therapy with stem-cell support. BPT comprised fixed doses of bendamustine (60 mg/m2) and prednisolone (100 mg), and escalating doses of thalidomide (50, 100, 200 mg). Treatment cycles were repeated every 28 d until the occurrence of maximum response, DLT, or disease progression. Twenty-four patients responded after at least two cycles (four complete remission, six very good partial remission, 14 partial remission). Median progression-free and overall survival for all patients was 11 and 19 months respectively. Only mild/moderate non-haematological side effects were observed and no patient developed dose-limiting haematotoxicity. Transient grade 3-4 neutropenia was reported in 12 patients, and grade 3-4 thrombocytopenia occurred in two patients. We conclude that BPT therapy was well tolerated in patients with relapsed or refractory MM, with a response rate higher than 80%. The maximum tolerated dose of thalidomide was not reached in this study. | ||
| 650 | 4 | |a advanced multiple myeloma | |
| 650 | 4 | |a bendamustine | |
| 650 | 4 | |a Phase I study | |
| 650 | 4 | |a prednisolone | |
| 650 | 4 | |a thalidomide | |
| 700 | 1 | |a Rozanski, Marta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Hoffmann, Franz Albert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boldt, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schwarzer, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ritter, Ute |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rohrberg, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schwalbe, Elke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uhlig, Jens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zehrfeld, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schirmer, Veronika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haas, Antje |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreibich, Ute |e VerfasserIn |4 aut | |
| 700 | 1 | |a Niederwieser, Dietger |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d Oxford [u.a.] : Wiley-Blackwell, 1955 |g 143(2008), 2, Seite 191-200 |h Online-Ressource |w (DE-627)269758941 |w (DE-600)1475751-5 |w (DE-576)09113997X |x 1365-2141 |7 nnas |a Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy results of a Phase I clinical trial |
| 773 | 1 | 8 | |g volume:143 |g year:2008 |g number:2 |g pages:191-200 |g extent:10 |a Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy results of a Phase I clinical trial |
| 856 | 4 | 0 | |u https://doi.org/10.1111/j.1365-2141.2008.07076.x |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2008.07076.x |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220114 | ||
| 993 | |a Article | ||
| 994 | |a 2008 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1786118777 |e 4035756415 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Wolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, Franz Albert Hoffmann, Thomas Boldt, Andreas Schwarzer, Ute Ritter, Robert Rohrberg, Elke Schwalbe, Jens Uhlig, Thomas Zehrfeld, Veronika Schirmer, Antje Haas, Ute Kreibich and Dietger Niederwieser for the East German Study Group of Haematology and Oncology (OSHO)"]},"origin":[{"dateIssuedKey":"2008","dateIssuedDisp":"24 September 2008"}],"relHost":[{"recId":"269758941","origin":[{"dateIssuedKey":"1955","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell","dateIssuedDisp":"1955-","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]"}],"name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"corporate":[{"role":"isb","display":"British Society for Haematology"},{"display":"European Hematology Association","role":"isb"}],"note":["Gesehen am 08.05.08"],"part":{"year":"2008","text":"143(2008), 2, Seite 191-200","issue":"2","volume":"143","pages":"191-200","extent":"10"},"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"title":[{"subtitle":"BJHaem : an official journal of the British Society for Haematology","title_sort":"British journal of haematology","title":"British journal of haematology"}],"pubHistory":["1.1955 -"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy results of a Phase I clinical trialBritish journal of haematology","id":{"eki":["269758941"],"issn":["1365-2141"],"zdb":["1475751-5"],"doi":["10.1111/(ISSN)1365-2141"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"]}],"recId":"1786118777","title":[{"subtitle":"results of a Phase I clinical trial","title_sort":"Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy","title":"Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy"}],"language":["eng"],"person":[{"role":"aut","display":"Pönisch, Wolfram","given":"Wolfram","family":"Pönisch"},{"role":"aut","display":"Rozanski, Marta","given":"Marta","family":"Rozanski"},{"role":"aut","display":"Goldschmidt, Hartmut","given":"Hartmut","family":"Goldschmidt"},{"family":"Hoffmann","given":"Franz Albert","display":"Hoffmann, Franz Albert","role":"aut"},{"display":"Boldt, Thomas","role":"aut","given":"Thomas","family":"Boldt"},{"given":"Andreas","family":"Schwarzer","role":"aut","display":"Schwarzer, Andreas"},{"family":"Ritter","given":"Ute","display":"Ritter, Ute","role":"aut"},{"role":"aut","display":"Rohrberg, Robert","family":"Rohrberg","given":"Robert"},{"family":"Schwalbe","given":"Elke","display":"Schwalbe, Elke","role":"aut"},{"given":"Jens","family":"Uhlig","role":"aut","display":"Uhlig, Jens"},{"family":"Zehrfeld","given":"Thomas","role":"aut","display":"Zehrfeld, Thomas"},{"display":"Schirmer, Veronika","role":"aut","given":"Veronika","family":"Schirmer"},{"family":"Haas","given":"Antje","display":"Haas, Antje","role":"aut"},{"family":"Kreibich","given":"Ute","role":"aut","display":"Kreibich, Ute"},{"family":"Niederwieser","given":"Dietger","role":"aut","display":"Niederwieser, Dietger"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1786118777"],"doi":["10.1111/j.1365-2141.2008.07076.x"]},"note":["Gesehen am 14.01.2022"]} | ||
| SRT | |a POENISCHWOCOMBINEDBE2420 | ||